Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Rhumbline Advisers

Rhumbline Advisers lowered its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 8.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 56,066 shares of the company’s stock after selling 5,365 shares during the quarter. Rhumbline Advisers owned approximately 0.08% of Kiniksa Pharmaceuticals worth $1,047,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals in the 1st quarter worth about $71,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Kiniksa Pharmaceuticals by 88.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,708 shares of the company’s stock worth $152,000 after acquiring an additional 3,611 shares during the last quarter. Bayesian Capital Management LP purchased a new stake in Kiniksa Pharmaceuticals in the first quarter valued at approximately $222,000. Dynamic Technology Lab Private Ltd acquired a new position in Kiniksa Pharmaceuticals during the fourth quarter worth approximately $213,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in Kiniksa Pharmaceuticals during the first quarter worth approximately $266,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ KNSA opened at $25.64 on Monday. The business has a 50-day moving average of $25.20 and a 200-day moving average of $21.25. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of 233.09 and a beta of 0.33. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $14.12 and a 1-year high of $27.92.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The firm had revenue of $108.30 million during the quarter, compared to the consensus estimate of $90.60 million. During the same quarter in the prior year, the business posted ($0.02) earnings per share. Kiniksa Pharmaceuticals’s revenue for the quarter was up 51.5% on a year-over-year basis. Research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.31 EPS for the current fiscal year.

Wall Street Analyst Weigh In

KNSA has been the topic of a number of research analyst reports. Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price on the stock. Wedbush boosted their target price on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $33.60.

Insider Activity

In related news, COO Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the sale, the chief operating officer now owns 119,911 shares in the company, valued at $3,226,805.01. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 136,124 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $25.65, for a total transaction of $3,491,580.60. Following the sale, the chief executive officer now directly owns 63,012 shares of the company’s stock, valued at $1,616,257.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eben Tessari sold 17,500 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total transaction of $470,925.00. Following the completion of the transaction, the chief operating officer now directly owns 119,911 shares in the company, valued at approximately $3,226,805.01. The disclosure for this sale can be found here. In the last three months, insiders sold 260,564 shares of company stock worth $6,727,929. 54.57% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.